Asthma Management Guidelines

Treatment Strategies

• The Global Initiative for Asthma (GINA) recommends a stepwise approach for asthma management, with inhaled corticosteroids (ICS) as the cornerstone, and ICS-formoterol combination as the preferred treatment for mild persistent asthma, according to the American Journal of Respiratory and Critical Care Medicine 1
• For moderate to severe asthma, GINA recommends daily maintenance ICS-formoterol plus as-needed ICS-formoterol as reliever (SMART therapy), as stated in the Journal of Allergy and Clinical Immunology 2
• The American Academy of Family Physicians suggests that daily low-dose ICS plus as-needed short-acting beta agonists (SABA) is an alternative approach for mild intermittent asthma, as published in the American family physician 3

Medication Classes

• Inhaled corticosteroids (ICS) are the most effective anti-inflammatory medication for persistent asthma, reducing airway inflammation, improving symptoms, lung function, and quality of life, as reported in the American family physician 3
• Long-acting beta2 agonists (LABAs) should never be used as monotherapy for asthma and are most effective when combined with ICS, according to the American family physician 3
• Formoterol has a rapid onset, making it suitable for both maintenance and reliever therapy, as stated in the Journal of Allergy and Clinical Immunology 2

Special Considerations

• Oral systemic corticosteroids are recommended for moderate to severe exacerbations, as suggested by the American family physician 3
• The American College of Chest Physicians recommends that asthma treatment should be stepped down if asthma is well-controlled for at least 3 months, as mentioned in the context of 4
• Symptom control does not equal elimination of exacerbation risk, especially in severe asthma, as highlighted in the American Journal of Respiratory and Critical Care Medicine 5
• Avoiding LABA monotherapy is crucial, as it increases the risk of asthma-related death, as warned by the American Thoracic Society in the context of 4

Asthma Control and Management

Assessment of Asthma Control

• The Global Initiative for Asthma defines asthma control across two domains, including current symptom control, with criteria such as daytime symptoms, nighttime awakenings, need for reliever medication, activity limitation, and lung function, as outlined by the Mayo Clinic Proceedings 6
• For children aged 5-11, assessment criteria are adjusted, with well-controlled asthma defined as having nighttime awakenings of ≤1 time/month, according to the Mayo Clinic Proceedings 7

Special Considerations

• Identification and reduction of exposure to allergens and irritants that trigger symptoms is recommended, as stated in the European Respiratory Journal 8
• Patients should receive written asthma action plans and training on proper inhaler technique, as recommended by the Journal of Allergy and Clinical Immunology 9

Asthma Management Recommendations

Introduction to Asthma Treatment

• The American Thoracic Society, as reflected in the Journal of Allergy and Clinical Immunology, suggests add-on treatments such as long-acting muscarinic antagonists (LAMA) before initiating phenotype-specific biologics in severe asthma patients 10

Patient Education

• The British Thoracic Society, as published in Thorax, recommends that all patients receive a written asthma action plan, training on proper inhaler technique, and a clear understanding of "relievers" versus "preventers" to empower them to self-adjust medications according to their plan 11
• The same guideline from the British Thoracic Society, published in Thorax, also emphasizes the importance of recognizing worsening symptoms and nocturnal symptoms in asthma management 11

Special Populations

• For children aged 0-2 years, diagnosis relies on symptoms rather than objective testing, and bronchodilator response is variable, according to the British Thoracic Society guidelines published in Thorax 11
• Pregnant women with worsening asthma should be referred for specialist consultation, as suggested by the British Thoracic Society guidelines in Thorax 11
• Patients with inhaled steroid concerns should use the lowest dose providing acceptable control, considering that short-term reductions in tibial growth rate occur at doses >400 µg/day in children, as noted in guidelines from the British Thoracic Society in Thorax 11

Asthma Management Guidelines

Diagnosis and Assessment

• The American Thoracic Society recommends that asthma diagnosis relies on symptoms rather than objective testing in children 0-4 years 12
• Severe exacerbation is defined by criteria including inability to complete sentences in one breath, respiratory rate >25 breaths/min, heart rate >110 beats/min, and peak expiratory flow (PEF) <50% predicted or personal best 13, 14
• Life-threatening features of asthma exacerbation include PEF <33% predicted, silent chest, cyanosis, or feeble respiratory effort, and bradycardia, hypotension, exhaustion, confusion, or coma 13, 14

Treatment and Management

• The Global Initiative for Asthma (GINA) recommends that doses of inhaled corticosteroids (ICS) >500 mcg/day carry significant systemic adverse effects, including adrenal suppression equivalent to 5 mg oral prednisone daily 15
• In children, doses of ICS >400 mcg/day cause short-term reductions in tibial growth rate 12
• The American College of Chest Physicians recommends that high-flow oxygen 40-60% should be initiated simultaneously with nebulized salbutamol 5 mg or terbutaline 10 mg via oxygen-driven nebulizer for severe exacerbations 13, 14
• The American Academy of Allergy, Asthma, and Immunology recommends that patients with comorbid asthma and allergen immunotherapy should be evaluated for asthma before initiating allergen immunotherapy (AIT) and assessed for asthma control before each subcutaneous immunotherapy (SCIT) injection 16

Patient Education and Monitoring

• The National Asthma Education and Prevention Program recommends that every patient must receive a written asthma action plan with specific PEF or symptom thresholds for medication adjustment, inhaler technique training, and clear distinction between "relievers" and "preventers" 12
• Well-controlled asthma requires all of the following over the past 4 weeks: daytime symptoms ≤2 days/week, no nighttime awakenings due to asthma, reliever use ≤2 days/week, and no activity limitation due to asthma 15, 17
• The American Thoracic Society recommends that patients with severe or uncontrolled asthma should not receive subcutaneous immunotherapy (SCIT) and that SCIT should be withheld temporarily if asthma control deteriorates 16

Asthma Control and Treatment

Introduction to Asthma Control

• The American Academy of Allergy, Asthma, and Immunology recommends that asthma control be assessed based on two domains: symptom control and future risk, with criteria including daytime symptoms, nighttime awakenings, reliever use, activity limitation, and lung function, as outlined in the Journal of Allergy and Clinical Immunology 18
• The Global Initiative for Asthma (GINA) classifies asthma into three control levels: controlled, partly controlled, and uncontrolled, based on the assessment of symptom control and future risk domains, with partly controlled asthma defined as meeting 1-2 symptom criteria and uncontrolled asthma defined as meeting fewer than 2 symptom criteria, according to the American Journal of Respiratory and Critical Care Medicine 19

Treatment Adjustment and Specialist Referral

• The American College of Allergy, Asthma, and Immunology recommends stepping up treatment when asthma is partly controlled or uncontrolled, or when a patient has had two or more exacerbations requiring oral corticosteroids in the past year, as stated in the Journal of Allergy and Clinical Immunology 18
• The American Thoracic Society suggests referring patients to an asthma specialist when they have difficulty achieving or maintaining control, require two or more bursts of oral corticosteroids in a year, or have an exacerbation requiring hospitalization, as recommended in the Journal of Allergy and Clinical Immunology 18

Asthma Management Guidelines

Introduction to Asthma Treatment

• The American College of Allergy, Asthma, and Immunology recommends that formoterol is the only LABA suitable for as-needed use due to its rapid onset, and salmeterol should never be used for SMART therapy, as LABAs must never be used as monotherapy, increasing asthma-related death risk 20
• The American Academy of Family Physicians notes that GINA no longer recommends doubling ICS dose for home management of exacerbations, as this strategy is ineffective 21

Special Populations

• The Global Initiative for Asthma recommends that children 6-11 years old should not use SMART therapy, and ICS doses >400 mcg/day can cause short-term reductions in tibial growth rate, and GINA does not recommend ICS-formoterol as reliever therapy in children 0-5 years old 20

Guideline Comparison

• The National Asthma Education and Prevention Program differs from GINA in several areas, including not recommending ICS-formoterol for intermittent asthma in adults, and recommending SMART at Steps 3-4 but not Step 5, whereas GINA recommends it through Step 5 20, 22

GINA Evidence‑Based Asthma Management Recommendations

Adults and Adolescents (≥ 12 years)

• Step 1 – Mild intermittent: An as‑needed combination of low‑dose inhaled corticosteroid (ICS) + formoterol is preferred; an alternative is as‑needed ICS + short‑acting β₂‑agonist (SABA) (Pediatrics 2021) 23.
• Step 2 – Mild persistent: Daily low‑dose ICS + as‑needed SABA is an evidence‑supported alternative (Pediatrics 2021) 23.
• Step 3 – Moderate persistent: The SMART (single‑maintenance‑and‑reliever‑therapy) regimen—daily low‑dose ICS‑formoterol with as‑needed ICS‑formoterol—is superior to higher‑dose ICS‑LABA plus SABA for preventing exacerbations (Pediatrics 2021) 23.
• Step 3 – Moderate persistent (alternative): Low‑to‑medium‑dose ICS‑LABA taken daily with as‑needed SABA is an accepted alternative (Journal of Allergy and Clinical Immunology 2007) 24.
• Step 4 – Moderate‑to‑severe persistent (alternative): Medium‑to‑high‑dose ICS‑LABA daily with as‑needed SABA is recommended when higher‑dose MART is not used (Journal of Allergy and Clinical Immunology 2007) 24.
• Step 5 – Severe persistent: Oral corticosteroids are reserved for last‑resort use because of significant adverse effects (Journal of Allergy and Clinical Immunology 2007) 24.

Children 5–11 years

• Step 1 – Mild intermittent: As‑needed SABA alone may be acceptable if symptoms occur ≤ 2 days/week (Journal of Allergy and Clinical Immunology 2007) 24.
• Step 1 – Mild intermittent (if symptoms > 2 days/week): Initiate low‑dose daily ICS (Journal of Allergy and Clinical Immunology 2007) 24.
• Step 2 – Mild persistent: Preferred therapy is daily low‑dose ICS; as‑needed SABA is used for quick relief (Journal of Allergy and Clinical Immunology 2007) 24.
• Step 3 – Moderate persistent: Preferred is daily low‑dose ICS‑LABA; an alternative is medium‑dose daily ICS alone (Journal of Allergy and Clinical Immunology 2007) 24.
• Step 4 – Moderate‑to‑severe persistent: Preferred is daily medium‑dose ICS‑LABA (Journal of Allergy and Clinical Immunology 2007) 24.
• Step 5 – Severe persistent: High‑dose daily ICS‑LABA is recommended; oral corticosteroids may be used if needed (Journal of Allergy and Clinical Immunology 2007) 24.
• Growth safety: Daily ICS doses > 400 µg can cause a short‑term reduction in tibial growth (~1 cm), mainly during the first few months of therapy (Journal of Allergy and Clinical Immunology 2007) 25. The therapeutic benefit of ICS outweighs this effect, so dosing should be titrated to the lowest effective level (Journal of Allergy and Clinical Immunology 2007) [25][24].

Children 0–4 years

• Start daily low‑dose ICS when a child has ≥ 4 wheezing episodes in the past year lasting > 1 day, affecting sleep, and a positive Asthma Predictive Index (parental asthma, atopic dermatitis, or aeroallergen sensitization; or ≥ 2 of: food sensitization, eosinophilia > 4 %, wheezing apart from colds) (Journal of Allergy and Clinical Immunology 2007) 24.
• Consider controller therapy if symptoms require treatment > 2 days/week for > 4 weeks, or if ≥ 2 exacerbations needed systemic corticosteroids within 6 months (Journal of Allergy and Clinical Immunology 2007) 24.
• Step 1: As‑needed SABA alone (Journal of Allergy and Clinical Immunology 2007) 24.
• Step 2: Daily low‑dose ICS (preferred controller) (Journal of Allergy and Clinical Immunology 2007) 24.
• Step 3: Medium‑dose ICS (Journal of Allergy and Clinical Immunology 2007) 24.
• Step 4: Medium‑dose ICS + either LABA or leukotriene modifier (Journal of Allergy and Clinical Immunology 2007) 24.
• Monitoring: Evaluate response for 4–6 weeks; if no benefit, discontinue therapy and reassess the diagnosis (Journal of Allergy and Clinical Immunology 2007; Mayo Clinic Proceedings 2009) [25][24].

Assessment of Asthma Control

• Well‑controlled asthma over the previous 4 weeks requires all of the following: daytime symptoms ≤ 2 days/week, no night‑time awakenings, reliever use ≤ 2 days/week, and no activity limitation (Mayo Clinic Proceedings 2009) 26.
• Partly or uncontrolled asthma is identified when 1–2 of the above criteria are not met (no citation needed).
• Step‑up indication: ≥ 2 exacerbations requiring oral corticosteroids in the past year (Mayo Clinic Proceedings 2009) 26.

Treatment Adjustment

• Step‑down criteria: Asthma well‑controlled for ≥ 3 months (Journal of Allergy and Clinical Immunology 2007) 24.
• ICS dose reduction: Decrease the daily ICS dose by 25–50 % every 3 months to find the minimum effective dose, with close monitoring for 2–6 weeks after each reduction (Journal of Allergy and Clinical Immunology 2007) 24.